Advances in pharmacotherapy for sickle cell disease: what is the current state of play?

References

• Power-Hays A, McGann PT. When actions speak louder than words - racism and sickle cell disease. N Engl J Med [Internet]. 2020 Nov 12;383(20):1902–1903. doi: 10.1056/NEJMp2022125
   PubMed Web of Science ®Google Scholar
• Kanter J, Smith WR, Desai PC, et al. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv [Internet]. 2020 Aug 25;4(16):3804–3813. doi: 10.1182/bloodadvances.2020001743
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials [Internet]. 1998 Feb 1;19(1):110–129. doi: 10.1016/S0197-2456(97)00099-8
   PubMedGoogle Scholar
• Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med [Internet]. 2005 Dec 29;353(26):2769–2778.
   PubMed Web of Science ®Google Scholar
• Lee MT, Piomelli S, Granger S, et al. STOP Study Investigators. Stroke prevention trial in sickle cell anemia (STOP): Extended follow-up and final results. Blood [Internet]. 2006 Aug 1;108(3):847–852. doi: 10.1182/blood-2005-10-009506
   PubMed Web of Science ®Google Scholar
• Kanter J, Phillips S, Schlenz AM, et al. Transcranial Doppler screening in a current cohort of children with sickle cell anemia: Results from the DISPLACE study. J Pediatr Hematol Oncol [Internet]. 2021 Nov 1;43(8):e1062–8. doi: 10.1097/MPH.0000000000002103
   PubMed Web of Science ®Google Scholar
• Sobczyk O, Gottardi E, Lefebvre M, et al. Evaluation of a prophylactic transfusion program on obstetric outcomes in pregnant women with sickle cell disease: A single centre retrospective cohort study. Eur J Obstet Gynecol Reprod Biol [Internet]. 2023 Nov 1;290:103–108. doi: 10.1016/j.ejogrb.2023.08.390
   PubMed Web of Science ®Google Scholar
• Malinowski AK, Shehata N, D’Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: A systematic review and meta-analysis. Blood [Internet]. 2015 Nov 19;126(21):2424,35; quiz 2437. doi: 10.1182/blood-2015-06-649319
   PubMed Web of Science ®Google Scholar
• Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med [Internet]. 1988 Dec 1;319(22):1447–1452. doi: 10.1056/NEJM198812013192204
   PubMed Web of Science ®Google Scholar
• Chou ST, Alsawas M, Fasano RM, et al. American society of hematology 2020 guidelines for sickle cell disease: Transfusion support. Blood Adv [Internet]. 2020 [cited 2024 May 6];4(2):327–355.doi: 10.1182/bloodadvances.2019001143
   PubMed Web of Science ®Google Scholar
• Choi J, Markantonis JE, De Simone N, et al. Hemoglobin S target of <50% as compared to 30% in chronic red cell exchange for secondary stroke prevention in sickle cell disease. J Clin Apher. 2023Dec;38(6):677–684. doi: 10.1002/jca.22078
   PubMedGoogle Scholar
• Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol [Internet]. 2017 Jun 1;177(5):703–716. doi: 10.1111/bjh.14575
   PubMed Web of Science ®Google Scholar
• Chou ST, Alsawas M, Fasano RM, et al. American society of hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv [Internet]. 2020 Jan 28;4(2):327–355. doi: 10.1182/bloodadvances.2019001143
   PubMed Web of Science ®Google Scholar
• Bhatia M, Sheth S. Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations. J Blood Med [Internet]. 2015 Jul 10;6:229–238. doi: 10.2147/JBM.S60515
   PubMedGoogle Scholar
• Agrawal RK, Patel RK, Shah V, et al. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus [Internet]. 2014 Jun 1;30(2):91–96. doi: 10.1007/s12288-013-0261-4
   PubMed Web of Science ®Google Scholar
• McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf [Internet]. 2015;14(11):1749–1758. doi: 10.1517/14740338.2015.1088827
   Google Scholar
• Steinberg MH. Fetal-like hemoglobin in sickle cell anemia. N Engl J Med [Internet]. 2022 Feb 17;386(7):689–691. doi: 10.1056/NEJMe2119760
   PubMed Web of Science ®Google Scholar
• Khargekar N, Banerjee A, Athalye S, et al. Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: A systematic review and meta-analysis. Syst Rev [Internet]. 2024 Feb 8;13(1):60–z. doi: 10.1186/s13643-024-02461-z
   PubMedGoogle Scholar
• Maier-Redelsperger M, Noguchi CT, de Montalembert M, et al. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian prospective study on sickle cell disease. Blood [Internet]. 1994 Nov 1;84(9):3182–3188. doi: 10.1182/blood.V84.9.3182.3182
   PubMed Web of Science ®Google Scholar
• McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf [Internet]. 2015;14(11):1749–1758. doi: 10.1517/14740338.2015.1088827
   PubMed Web of Science ®Google Scholar
• Treadwell MJ, Du L, Bhasin N, et al. Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: report from a U.S. regional collaborative. Front Genet [Internet]. 2022 Aug 26;13:921432. doi: 10.3389/fgene.2022.921432
   PubMed Web of Science ®Google Scholar
• Adekile AD, Gupta R, Al-Khayat A, et al. Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation. Pediatr Blood Cancer [Internet]. 2019 Feb 1;66(2):e27503. doi: 10.1002/pbc.27503
   PubMed Web of Science ®Google Scholar
• Nawaiseh M, Roto A, Nawaiseh Y, et al. Risk factors associated with sickle cell retinopathy: findings from the cooperative study of sickle cell disease. Int J Retina Vitreous [Internet]. 2022 Sep 22;8(1):68–8. doi: 10.1186/s40942-022-00419-8
   PubMedGoogle Scholar
• Berthaut I, Bachir D, Kotti S, et al. Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood [Internet]. 2017 Nov 23;130(21):2354–2356. doi: 10.1182/blood-2017-03-771857
   PubMed Web of Science ®Google Scholar
• Pecker LH, Hussain S, Christianson MS, et al. Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the multicenter study of hydroxycarbamide. Br J Haematol [Internet]. 2020 Dec 1;191(5):880–887. doi: 10.1111/bjh.16976
   PubMed Web of Science ®Google Scholar
• Howard J, Hemmaway CJ, Telfer P, et al. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood [Internet]. 2019 Apr 25;133(17):1865–1875. doi: 10.1182/blood-2018-08-868893
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Hoppe CC, Ataga KI, et al. HOPE Trial Investigators. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med [Internet]. 2019 Aug 8;381(6):509–519. doi: 10.1056/NEJMoa1903212
   PubMed Web of Science ®Google Scholar
• Henry ER, Metaferia B, Li Q, et al. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood [Internet]. 2021 Sep 30;138(13):1172–1181. doi: 10.1182/blood.2021012070
   PubMed Web of Science ®Google Scholar
• Beutler E. The effect of methemoglobin formation in sickle cell disease. J Clin Invest [Internet]. 1961 Oct;40(10):1856–1871. doi: 10.1172/JCI104410
   PubMed Web of Science ®Google Scholar
• Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett [Internet]. 2017 Jan 23;8(3):321–326. doi: 10.1021/acsmedchemlett.6b00491
   PubMed Web of Science ®Google Scholar
• Achebe MO, Hassab HM, Al-Kindi S, et al. Over 4 years of safety and efficacy with voxelotor treatment for patients with sickle cell disease: Updated results from an open-label extension of the phase 3 HOPE trial. Blood [Internet]. 2023 [cited 2024 May 6];142(Supplement 1):2527. doi: 10.1182/blood-2023-188616
   Google Scholar
• Curtis SA, Betancourt J, Kottapalli N, et al. Voxelotor use in adults with sickle cell disease in a real-world setting. Am J Hematol [Internet]. 2022 Mar 1;97(3):E125–8. doi: 10.1002/ajh.26453
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med [Internet]. 2017 Feb 2;376(5):429–439. doi: 10.1056/NEJMoa1611770
   PubMed Web of Science ®Google Scholar
• Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood [Internet]. 2017 May 18;129(20):2719–2726. doi: 10.1182/blood-2017-02-765891
   PubMed Web of Science ®Google Scholar
• Kanter J, Brown RC, Norris C, et al. Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease. Blood Adv. 2023 [cited 2024 May 6];7(6):943–952. doi: 10.1182/bloodadvances.2022008209
   PubMed Web of Science ®Google Scholar
• Abboud MR, Cançado RD, De Montalembert M, et al. Efficacy, safety, and biomarker analysis of 5 mg and 7.5 mg doses of crizanlizumab in patients with sickle cell disease: Primary analyses from the phase III STAND study. Blood [Internet]. 2023 [cited 2024 May 6];142(Supplement 1):272. doi: 10.1182/blood-2023-185429
   Google Scholar
• Niihara Y, Zerez CR, Akiyama DS, et al. Oral L-glutamine therapy for sickle cell anemia: I. subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol [Internet]. 1998 Jun;58(2):117–121. doi: 10.1002/(SICI)1096-8652(199806)58:2<117:AID-AJH5>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Niihara Y, Miller ST, Kanter J, et al. Investigators of the Phase 3 trial of l-glutamine in sickle cell disease. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med [Internet]. 2018 Jul 19;379(3):226–235. doi: 10.1056/NEJMoa1715971
   PubMed Web of Science ®Google Scholar
• Liu P, Yao M, Gong Y, et al. Benchmarking the human leukocyte antigen typing performance of three assays and seven next-generation sequencing-based algorithms. Front Immunol [Internet]. 2021 Mar 31;12:652258. doi: 10.3389/fimmu.2021.652258
   PubMed Web of Science ®Google Scholar
• Choo SY. The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J [Internet]. 2007 Feb 28;48(1):11–23. doi: 10.3349/ymj.2007.48.1.11
   PubMed Web of Science ®Google Scholar
• Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program [Internet]. 2011;2011(1):273–279. doi: 10.1182/asheducation-2011.1.273
   PubMedGoogle Scholar
• Tozatto-Maio K, Torres MA, Degaide NHS, et al. HLA-matched unrelated donors for patients with sickle cell disease: Results of international donor searches. Biol Blood Marrow Transplant [Internet]. 2020 Nov 1;26(11):2034–2039. doi: 10.1016/j.bbmt.2020.07.015
   PubMed Web of Science ®Google Scholar
• Khemani K, Katoch D, Krishnamurti L. Curative therapies for sickle cell disease. Ochsner J [Internet]. 2019 Jan 1;19(2):131–137. doi: 10.31486/toj.18.0044
   PubMed Web of Science ®Google Scholar
• Elhasid R. The penny has dropped for sickle cell disease. Blood. 2017 [cited 2024 May 6];129(11):1412–1413. doi:10.1182/blood-2016-12-758722
   PubMed Web of Science ®Google Scholar
• Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med [Internet]. 2022 Feb 17;386(7):617–628. doi: 10.1056/NEJMoa2117175
   PubMed Web of Science ®Google Scholar
• Balint MT, Lemajic N, Jurisic V, et al. An evidence-based and risk-adapted GSF versus GSF plus plerixafor mobilization strategy to obtain a sufficient CD34(+) cell yield in the harvest for autologous stem cell transplants. Transl Oncol [Internet]. 2024 Jan 1;39:101811. doi: 10.1016/j.tranon.2023.101811
   PubMed Web of Science ®Google Scholar
• Fitzhugh CD, Hsieh MM, Bolan CD, et al. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: Time for a moratorium? Cytotherapy [Internet]. 2009;11(4):464–471. doi: 10.1080/14653240902849788
   PubMed Web of Science ®Google Scholar
• Frangoul H, Locatelli F, Sharma A, et al. CLIMB SCD-121 Study Group. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med [Internet]. 2024 Apr 24;390(18):1649–1662. doi: 10.1056/NEJMoa2309676
   PubMedGoogle Scholar
• Bluebird bio I. Lyfgenia Prescribing Information [Internet]. Available from: https://www.bluebirdbio.com/-/media/bluebirdbio/Corporate%20COM/Files/Lyfgenia/LYFGENIA_Prescribing_Information.pdf
   Google Scholar
• Casgevy Prescribing Information [Internet]. Available from: https://www.casgevyhcp.com/sites/default/files/uspi-ppi_exagamglogene_autotemcel.pdf
   Google Scholar
• Nickel RS, Maher JY, Hsieh MH, et al. Fertility after curative therapy for sickle cell disease: A comprehensive review to guide care. J Clin Med [Internet]. 2022 Apr 21;11(9):2318. doi: 10.3390/jcm11092318
   PubMed Web of Science ®Google Scholar
• Pecker LH, Maher JY, Law JY, et al. Risks associated with fertility preservation for women with sickle cell anemia. Fertil Steril [Internet]. 2018 Sep 1;110(4):720–731. doi: 10.1016/j.fertnstert.2018.05.016
   PubMed Web of Science ®Google Scholar
• Chaguaceda C, Aguilera-Jimenez V, Gutierrez G, et al. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. Int J Clin Pharm [Internet]. 2020 Apr 1;42(2):351–354. doi: 10.1007/s11096-020-00977-7
   PubMed Web of Science ®Google Scholar
• Stenger EO, Shenoy S, Krishnamurti L. How I treat sickle cell disease with hematopoietic cell transplantation. Blood [Internet]. 2019 Dec 19;134(25):2249–2260. doi: 10.1182/blood.2019000821
   PubMed Web of Science ®Google Scholar
• Negre O, Eggimann A, Beuzard Y, et al. Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene. Hum Gene Ther [Internet]. 2016 Feb 1;27(2):148–165. doi: 10.1089/hum.2016.007
   PubMed Web of Science ®Google Scholar
• Ribeil J, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. [2017 Mar 2];376(9):848–855. doi: 10.1056/NEJMoa1609677
   PubMed Web of Science ®Google Scholar
• Leonard A, Tisdale JF. Gene therapy for sickle cell disease. Hematology. 2023. 2023(1):542–547. doi: 10.1182/hematology.2023000487
   PubMedGoogle Scholar
• Bank A, Dorazio R, Leboulch P. A Phase I/II clinical trial of β-globin gene therapy for β-Thalassemia. Ann N Y Acad Sci. [Internet]. 2005;1054(1):308–316. doi: 10.1196/annals.1345.007
   PubMedGoogle Scholar
• Kanter J, Thompson AA, Pierciey FJJ, et al. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am J Hematol. [Internet]. 2023 Jan 1;98(1):11–22. doi: 10.1002/ajh.26741
   PubMed Web of Science ®Google Scholar
• Kanter J, Thompson AA, Kwiatkowski JL, et al. Efficacy, safety, and health-related quality of life (HRQOL) in patients with sickle cell disease (SCD) who have received lovotibeglogene autotemcel (Lovo-cel) gene therapy: Up to 60 months of follow-up. 2023 [cited 2024 May 5];142(Supplement 1):1051. doi: 10.1182/blood-2023-174229
   Google Scholar
• Goyal S, Tisdale J, Schmidt M, et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022 Jan 13;386(2):138–147. doi: 10.1056/NEJMoa2109167
   PubMed Web of Science ®Google Scholar
• Cradick TJ, Fine EJ, Antico CJ, et al. CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 2013 Nov 01;41(20):9584–9592. doi: 10.1093/nar/gkt714
   PubMed Web of Science ®Google Scholar
• Bak RO, Dever DP, Porteus MH. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc. 2018 Feb 01;13(2):358–376. doi: 10.1038/nprot.2017.143
   PubMed Web of Science ®Google Scholar
• Basak A, Sankaran VG. Regulation of the fetal hemoglobin silencing factor BCL11A. Ann NY Acad Sci. [2016 Mar 1];1368(1):25–30. doi: 10.1111/nyas.13024
   PubMedGoogle Scholar
• Bauer DE, Orkin SH. Hemoglobin switching’s surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev. [2015 Aug 1];33:62–70. doi: 10.1016/j.gde.2015.08.001
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Fetal hemoglobin in sickle hemoglobinopathies: high HbF genotypes and phenotypes. J Clin Med. [2020 Nov 23];9(11):3782. doi: 10.3390/jcm9113782
   PubMed Web of Science ®Google Scholar
• Frangoul H, Locatelli F, Sharma A, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. [Internet]. 2024 Apr 24;390(18):1649–1662. doi: 10.1056/NEJMoa2309676
   PubMedGoogle Scholar
• National Alliance of Sickle Cell Centers. Available from: https://sicklecellcenters.org/
   Google Scholar
• Xu JZ, Vercellotti GM. Pyruvate kinase activators: Targeting red cell metabolism in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2023 [cited 2024 May 6];2023(1):107–113. doi: 10.1182/hematology.2023000467
   PubMedGoogle Scholar
• Saraf SL, Abdullahi SU, Akinsete AM, et al. Preliminary results from a multicenter phase 2/3 study of next-generation HbS polymerization inhibitor GBT021601 for the treatment of patients with sickle cell disease [Internet]. Blood. 2023 [cited 2024 May 6];142(Supplement 1):274. doi: 10.1182/blood-2023-177781
   PubMedGoogle Scholar
• Fitz EM, Allen A, Edwards L, et al. HbF inducing eed inhibitor ftx-6058 selectively and reversibly impacts bone marrow in wild-type mice [Internet]. Blood. 2023 [cited 2024 May 6];142(Supplement 1):5265. doi: 10.1182/blood-2023-190115
   Google Scholar
• Ting PY, Borikar S, Kerrigan JR, et al. Targeted degradation of the wiz transcription factor for gamma globin de-repression. [Internet]. 2023 [cited 2024 May 20];142(Supplement 1):2. doi: 10.1182/blood-2023-179331
   Google Scholar
• Kato GJ, Senior MB, Goldstein B. A red blood cell disease meets a company with a plasma protein heritage. Available from: https://file://es/CANCER-FH-BenignHeme/Clinic%20Documents/CSL.pdf
   Google Scholar
• Pharmacokinetics, pharmacodynamics and safety of epeleuton in patients with sickle cell disease. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05861453
   Google Scholar
• Dai Y, Hill K, Harris D, et al. A phase 2a, randomized, open-label study to evaluate multiple dosing regimens of subcutaneous ALXN1820 in adult patients with sickle cell disease. [Internet]. Blood. 2022 [cited 2024 May 20];140(Supplement 1):8298–8299. doi: 10.1182/blood-2022-166694
   Google Scholar
• Geng X, Mihaila R, Yuan Y, et al. Inclacumab, a fully human anti-P-selectin antibody, directly binds to PSGL-1 binding region and demonstrates robust and durable inhibition of cell adhesion [Internet]. Blood. 2020 [cited 2024 May 20];136(Supplement 1):10–11. doi: 10.1182/blood-2020-140530
   Google Scholar
• A study of a single dose of inclacumab to reduce re-admission in participants with sickle cell disease and recurrent vaso-occlusive crises. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04927247
   Google Scholar
• Darbari DS, Liljencrantz J, Ikechi A, et al. Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant. Br J Haematol. 2019 Feb 1;184(4):690–693. doi: 10.1111/bjh.15169
   PubMed Web of Science ®Google Scholar